17,679 reports of this reaction
4.8% of all APREMILAST reports
#4 most reported adverse reaction
HEADACHE is the #4 most commonly reported adverse reaction for APREMILAST, manufactured by Amgen, Inc. There are 17,679 FDA adverse event reports linking APREMILAST to HEADACHE. This represents approximately 4.8% of all 370,200 adverse event reports for this drug.
Patients taking APREMILAST who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among APREMILAST users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for APREMILAST:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 17,679 FDA reports for APREMILAST. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 4.8% of all adverse event reports for APREMILAST, making it a notable side effect.
If you experience headache while taking APREMILAST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.